Abstract 620P
Background
Cancer constitutes a major burden to global health and the critical role of early diagnosis for cancer management is self-evident. Even though various miRNA-based signatures have been developed, their clinical utilization is limited due to various reasons. In this article, we innovatively developed a signature based on pairwise expression of miRNAs (miRPs) for pan-cancer diagnosis using machine learning approach.
Methods
miRNA spectrum of 15832 patients with 13 different cancers from 10 cohorts were analyzed. 15148 patients were divided into training, validation, and test sets with a ratio of 7:2:1, while 648 patients were utilized as external test. Pairwise comparison was performed to generate miRP score, defined by the comparison between two miRNAs, in training set. Five different machine-learning (ML) algorithms (XGBoost, SVM, RandomForest, LASSO, and Logistic) were adopted for signature construction. The best ML algorithm and the optimal number of miRPs included were identified using AUC and youden index in validation. Performance of the ideal model was evaluated in test and external set based on AUC, Youden index, positive predictive value (PPV), negative predictive value (NPV), sensitivity, specificity, and accuracy. The AUC of entire cohorts was compared to previously published 25 signatures.
Results
The Random Forest approach including 31 miRPs (31-miRP) outperformed others and was retained for further evaluation. The AUC of 31-miRP ranges 0.980-1.000 in different set. Remarkably, 31-miRP exhibited advantages in differentiating different cancers from normal tissues. Moreover, 31-miRP demonstrate superiorities in detecting early-stage cancers, with AUC ranging from 0.961-0.998. Compared to previously published 25 different signatures, 31-miRP also demonstrated clear advantages. Remarkably, 31-miRP also exhibited promising capabilities in differentiating cancers from corresponding benign lesions.
Conclusions
The 31-miRP exhibited outstanding diagnostic performance, characterized by high accuracy and sensitivity, thereby holding potential as a reliable tool for cancer diagnosis at early stage. Nevertheless, its effectiveness still warrants further investigation in real-world setting in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CAMS Innovation Fund for Medical Sciences (No.2021-I2M-1-050); National Natural Science Foundation for Young Scientists of China (No. 82203025).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract